# Washington University School of Medicine: Phase 2 study in Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC) (17 participants)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Washington University School of Medicine |
| Sponsor type | Academic and hospital |
| Study | Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer |
| NCT ID | NCT07914309 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Triple Negative Breast Cancer; Triple Negative Breast Cancer (TNBC); Breast Cancer |
| Intervention types | drug, biological |
| Target enrollment | 17 |
| Site countries | United States |
| Posted | 2026-11-03 |
| Planned start | 2026-11-30 |
| Event | Newly registered study |
| Event date | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07914309). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.